A beta-adrenergic agonist. Nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. It is used in the treatment of peripheral vascular disorders and premature labor.
Nylidrin has been studied across 17 research domains including ❤️ Cardiovascular, 😴 Sleep, 👁️ Vision & Eye, 🧠 Focus & Attention, 🫘 Kidney. The primary research focus is ❤️ Cardiovascular with 18% of studies addressing this area.
The following compounds share molecular targets with Nylidrin, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Nylidrin is generated deterministically from 90 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.